New application of human-derived lactolectin subtype protein

A technology of lactagglutinin and application, which is applied in the field of human-derived lactaglutinin subtype protein, can solve the problems of unsatisfactory effect and other problems, and achieve the effects of reducing blood-brain barrier leakage, small dosage and short effect time.

Pending Publication Date: 2022-01-07
GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, except for Nimoton, which is considered to have partial curative effect on patients with spontaneous subarachnoid hemorrhage, there are no other recognized effective clinical drugs at home and abroad, and the effects of other preventive measures that have been clinically applied are not ideal. deeply hurt

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of human-derived lactolectin subtype protein
  • New application of human-derived lactolectin subtype protein
  • New application of human-derived lactolectin subtype protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Lactadherin protein can reduce death and improve prognosis in TBI mice

[0086] 1.1 Objects and methods

[0087] 1.1.1 Experimental mice and instruments

[0088] All experimental mice were from Jackson Laboratory in the United States, and male C57 / BL6 black mice aged 8-20 weeks were used in the experiments, with a body weight ranging from 20 to 26 g. The mice were kept in the Specific Pathogen Free (SPF) grade animal breeding room of BloodWorks Northwest Research Institute. All experimental mice were fed with standard pellet feed and had free access to water. 250Iux, kept by professional animal breeders under the conditions of alternation of day and night.

[0089]

[0090]

[0091] 1.1.2 Experimental reagents

[0092]

[0093]

[0094] 1.1.3 Experimental method

[0095] 1.1.3.1 Preparation of BDMP by Gradient Centrifugation of Mouse Brain Tissue Homogenate

[0096] (1) Take the brain tissue of C57BL / 6 mice frozen in liquid nitrogen, put it in room temp...

Embodiment 2

[0166] Inhibitory effect of Lactadherin protein on mouse TBI-AC

[0167] 2.1 Objects and methods

[0168] 2.1.1 Experimental mice and instruments

[0169] All experimental mice were from Jackson Laboratory in the United States, and male C57 / BL6 black mice aged 8-20 weeks were used in the experiments, with a body weight ranging from 20 to 26 g. The mice were kept in the Specific Pathogen Free (SPF) grade animal breeding room of BloodWorks Northwest Research Institute. All experimental mice were fed with standard pellet feed and had free access to water. 250Iux, kept by professional animal breeders under the conditions of alternation of day and night.

[0170]

[0171]

[0172] 2.1.2 Experimental reagents

[0173]

[0174]

[0175] 2.1.3 Experimental method

[0176] 2.1.3.1 Determination of coagulation time of coagulation factor Xa

[0177] Take the blood of C57 / BL6 mice 1 hour before the TBI blow and 1 hour, 3 hours, and 6 hours after the blow (periorbital oute...

Embodiment 3

[0246] In vivo experiments to study the mechanism of action of Lactadherin protein

[0247] 3.1 Objects and methods

[0248] 3.1.1 Experimental mice and instruments

[0249] All experimental mice were from Jackson Laboratory in the United States, and male C57 / BL6 black mice aged 8-20 weeks were used in the experiments, with a body weight ranging from 20 to 26 g. The mice were kept in the Specific Pathogen Free (SPF) grade animal breeding room of BloodWorks Northwest Research Institute. All experimental mice were fed with standard pellet feed and had free access to water. 250Iux, kept by professional animal breeders under the conditions of alternation of day and night.

[0250]

[0251]

[0252] 3.1.2 Experimental reagents

[0253]

[0254]

[0255] 3.1.3 Experimental method

[0256] 3.1.3.1 Biotinylated BDMPs

[0257] Use a commercially purchased EZ-Link TM Sulfo-NHS-Biotin kit (ThermoFisher Scientific, Waltham, MA)

[0258] (1) Wash the extracted BDMP once ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention provides a new application of human-derived lactolectin subtype protein, the human-derived lactolectin subtype protein can be used for preparing a medicine for treating diseases caused by BDMP, as the Lactadherin protein can be taken from human blood macrophages and can also be massively obtained through in-vitro cell culture and genetic engineering expression, the dosage of the Lactadherin protein for treating vasospasm is small, the effect exerting time is extremely short, and the effect is very good. The human-derived lactolectin subtype protein can fully meet the clinical application standard after bioengineering treatment,due to the fact that the Lactadherin protein is the protein normally secreted in the human body and has good safety and good practicality.

Description

[0001] This application is a divisional application of the invention patent application with the application number 201810592824.0 "New uses of human-derived lectin subtype protein". The filing date of the original application is: 2018-06-11. technical field [0002] The invention relates to a new application of a human milk agglutinin subtype protein. Background technique [0003] Traumatic brain injury (traumatic brain injury, TBI) has high morbidity, disability and mortality, and it is difficult to control the primary injury. Therefore, controlling the secondary brain injury after TBI has become an important intervention target to improve the prognosis of patients. point. Traumatic brain injury-associated coagulopathy (TBI-AC) and excessive immune inflammatory response after TBI are important causes of death and disability after injury, but the mechanism is still unclear and the clinical treatment effect is not good. After TBI, brain-derived microparticles (BDMP) can be ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P9/10A61P11/00A61P25/00A61P25/02
CPCA61K38/1732A61P9/10A61P25/00A61P11/00A61P25/02
Inventor 张建宁董京飞周源赵子龙田野江荣才
Owner GENERAL HOSPITAL OF TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap